Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals: Innovating in mental health with safer, effective biotech solutions.
Gilgamesh Pharmaceuticals: Innovating in mental health with safer, effective biotech solutions.
Founded with a mission to revolutionize mental health treatment, Gilgamesh Pharmaceuticals is a clinical stage biotechnology company focused on developing innovative new chemical entities (NCEs). Leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience, and drug development expertise, the company aims to create rapid-acting and long-lasting therapies that target the root causes of neurological diseases. Their market focus is on precision psychiatric therapies that are orally bioavailable and move beyond symptom management.
Notable for its experienced team with a track record of successful biotech exits and inventions, Gilgamesh Pharmaceuticals has garnered attention from key investors in the biotech sector. The company has made significant strides in mental health science, utilizing an AI-powered discovery and translational platform to accelerate drug development. Their impact lies in the potential to offer safer, more effective treatments for mental health conditions, setting new standards in the industry.
Companies similar to Gilgamesh Pharmaceuticals include Mindstate Design Labs, Alto Neuroscience, Reset Pharmaceuticals and Sensorium Therapeutics.
Gilgamesh Pharmaceuticals was founded in 2019.
Gilgamesh Pharmaceuticals' headquarters is located in New York City, NY, US.
Gilgamesh Pharmaceuticals' most recent funding round was for $39M (USD) in December 2022.
As of Dec 15, 2022, Gilgamesh Pharmaceuticals has disclosed funding of $68.4M (USD). Undisclosed round amounts are excluded.
Gilgamesh Pharmaceuticals has 22 employees as of Feb 5, 2024.
Sensorium Therapeutics
sensorium.bio
